CY2130B1 - Enzyme inactivators - Google Patents

Enzyme inactivators

Info

Publication number
CY2130B1
CY2130B1 CY9900015A CY9900015A CY2130B1 CY 2130 B1 CY2130 B1 CY 2130B1 CY 9900015 A CY9900015 A CY 9900015A CY 9900015 A CY9900015 A CY 9900015A CY 2130 B1 CY2130 B1 CY 2130B1
Authority
CY
Cyprus
Prior art keywords
uracil
substituted
group
enzyme inactivators
halogen
Prior art date
Application number
CY9900015A
Other languages
English (en)
Inventor
Thomas Spector
David John Porter
George Rahim Saad
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909015896A external-priority patent/GB9015896D0/en
Priority claimed from GB909025039A external-priority patent/GB9025039D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CY2130B1 publication Critical patent/CY2130B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY9900015A 1990-07-19 1999-07-07 Enzyme inactivators CY2130B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909015896A GB9015896D0 (en) 1990-07-19 1990-07-19 Enzyme inactivators
GB909025039A GB9025039D0 (en) 1990-11-17 1990-11-17 Enzyme inactivators

Publications (1)

Publication Number Publication Date
CY2130B1 true CY2130B1 (en) 2002-06-21

Family

ID=26297354

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9900015A CY2130B1 (en) 1990-07-19 1999-07-07 Enzyme inactivators

Country Status (12)

Country Link
US (3) US6177436B1 (pt)
EP (2) EP0539442B1 (pt)
JP (2) JP3094036B2 (pt)
AT (1) ATE161722T1 (pt)
CY (1) CY2130B1 (pt)
DE (1) DE69128626T2 (pt)
DK (1) DK0539442T3 (pt)
ES (1) ES2111569T3 (pt)
GR (1) GR3026487T3 (pt)
HK (1) HK1004324A1 (pt)
SG (1) SG49855A1 (pt)
WO (1) WO1992001452A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
EP0586523A4 (en) * 1991-05-15 1995-11-29 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
GB9322795D0 (en) * 1993-11-05 1993-12-22 Wellcome Found Novel compounds
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
EP1569658A4 (en) 2001-12-20 2007-05-30 Pharmassett Ltd TREATMENT OF EPSTEIN-BARR VIRUS, INFECTION WITH KAPOSI-ASSOCIATED SARCOMA HERPESVIRUS AND ABNORMAL CELL PROLIFERATION
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
JP4910294B2 (ja) * 2005-02-17 2012-04-04 大日本印刷株式会社 カラーフィルタ基板および液晶表示パネル
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
CA2777546C (en) * 2009-10-14 2019-11-05 Adherex Technologies, Inc. Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124765A (en) 1975-05-13 1978-11-07 Ono Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
DE2522369A1 (de) * 1975-05-21 1976-12-02 Ono Pharmaceutical Co 5-fluoruracilderivate und verfahren zu ihrer herstellung
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
US4719214A (en) * 1985-07-25 1988-01-12 Southern Research Institute Carbocyclic analogues of thymine nucleosides
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US4874602A (en) * 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
KR950006713B1 (ko) * 1988-03-31 1995-06-21 미쓰비시 가세이 가부시끼가이샤 6-치환 비환식 피리미딘뉴클레오시드 유도체 및 그 유도체를 유효성분으로 하는 항 비루스제
NL8800942A (nl) 1988-04-12 1989-11-01 Lely Nv C Van Der Landbouwmachine.
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
US5643913A (en) 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds

Also Published As

Publication number Publication date
JP3094036B2 (ja) 2000-10-03
EP0711555A2 (en) 1996-05-15
DE69128626D1 (de) 1998-02-12
SG49855A1 (en) 1998-06-15
HK1004324A1 (en) 1998-11-20
US6177436B1 (en) 2001-01-23
ATE161722T1 (de) 1998-01-15
WO1992001452A1 (en) 1992-02-06
EP0711555A3 (pt) 1996-06-26
US6221852B1 (en) 2001-04-24
GR3026487T3 (en) 1998-07-31
US6586440B2 (en) 2003-07-01
DK0539442T3 (da) 1998-09-07
ES2111569T3 (es) 1998-03-16
JP2000297076A (ja) 2000-10-24
EP0539442B1 (en) 1998-01-07
DE69128626T2 (de) 1998-05-20
JP3359319B2 (ja) 2002-12-24
EP0539442A1 (en) 1993-05-05
JPH06502619A (ja) 1994-03-24
US20010025033A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
DK0453127T3 (da) Behandling af katarakt med 15-keto-prostaglandinforbindelser
AU8559891A (en) Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JO2035B1 (en) Pyrazine compounds
BG101422A (en) Benzoxazole derivatives as bronchodilating compounds
HK1012339A1 (en) 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivatives
EP0976722A4 (en) benzamidine
HK1004324A1 (en) Enzyme inactivators
UA35550C2 (uk) Похідні урацилу, що проявляють гербіцидну активність
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
DK0467564T3 (da) Behandling af inflammatoriske sygdomme med 15-ketoprostaglandinforbindelser
MXPA03001081A (es) Medicamento anti-inflamatorio.
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser
DK0625520T3 (da) Thiazolotriazol- og thiazolodiazolderivater med fungicid aktivitet
NZ333854A (en) Intermediates for the preparation of 2-imidazoline-5-ones
DK0469782T3 (da) Behandling af katarakt med prostacyclinforbindelser
MXPA01008308A (es) Proceso para la preparacion de compuestos de 6-(perfluoroalquil) uracilo.
MXPA01008189A (es) Proceso para la preparacion de compuestos 6-)perfluoroalquil) uracilo a partir de compuestos de urea.
SU1730839A1 (ru) Тиофосфорилокситиенилвинилметилсульфиды, обладающие акарицидной активностью
SU1746666A1 (ru) Замещенные 3-аминометиленпирролидин-2,4-дионы, обладающие противосудорожной активностью
GR3025084T3 (en) Acrylic derivatives of 2-thiazolypyrroles having a fungicidal activity